cell-therapy-public-health-congress-2019-keynote

Note:

Page 16

April 15-16, 2019 | Milan, Italy

PUBLIC HEALTH,

EPIDEMIOLOGY AND NUTRITION

World Congress on

CELL AND GENE THERAPY

International Conference on

OF EXCELLENCE

IN INTERNATIONAL

MEETINGS

YEARS

Joint Event on

Cell and Gene Therapy 2019 & Public Health Congress 2019

Archives of General Internal Medicine | ISSN: 2591-7951 | Volume 3

tively non-toxic lymphoablating small molecule such as AVM0703 will expand the opportunity for HSCGT. Spontaneous

lymphocyte recovery is observed within 14 days. AVM0703 enhances the efficacy of autologous concentrated intra-ar-

ticular bone marrow injections to treat knee arthritis, accelerates G-CSF-mediated mobilization of HSC into peripheral

blood and dramatically enhances CART efficacy against melanoma. AVM0703 is being developed as a replacement

for chemotherapy preconditioning (PC) required before allogeneic stem cell transplant (allo Tx), Autologous Hema-

topoietic Stem Cell Based Gene Therapy (AHSCGT) or Adoptive Cell Therapy (ACT). AVM0703 is being developed as a

stand-alone treatment for direct apoptotic killing of relapsed/refractory lymphocytic leukemia, lymphoma andmultiple

myeloma and for residual HIV and steroid-resistant GvHD.